Name: New Advances in Dyslipidemia (en Inglés)
Price: 1539.56 MXN
Availability: InStock
Author: Wong, Nathan
ISBN: 9783036598710

Envío gratis

portada New Advances in Dyslipidemia (en Inglés)

Formato

Libro Físico

Editorial

Mdpi AG

Autor

Wong, Nathan

Idioma

Inglés

N° páginas

214

Encuadernación

Tapa Dura

Dimensiones

24.4 x 17.0 x 1.9 cm

Peso

0.66 kg.

ISBN13

9783036598710

Categorías

Farmacología

New Advances in Dyslipidemia (en Inglés)

Wong, Nathan (Autor) · Mdpi AG · Tapa Dura

Libro Nuevo

$ 1,539.56

$ 2,565.93

Ahorras: $ 1,026.37

40% descuento

Envío normal

Origen: Estados Unidos (Costos de importación incluídos en el precio)

Se enviará desde nuestra bodega entre el Viernes 19 de Julio y el Lunes 29 de Julio.

Lo recibirás en cualquier lugar de México entre 1 y 3 días hábiles luego del envío.

Reseña del libro "New Advances in Dyslipidemia (en Inglés)"

Dyslipidemia is an important risk factor for atherosclerotic cardiovascular disease (ASCVD). However, despite current traditional therapies (e.g., statins), significant residual risks for the onset of ASCVD remain, warranting the need to better understand newer therapeutic options for diminishing this prospect. This Special Issue will focus on state-of-the-art concepts in the evaluation and management of dyslipidemia, including the rationale for newly set goals in the lipid treatment of this disease given the recent international guidelines, global trends in the epidemiology of dyslipidemia, the latest concepts and therapies in the evaluation and management of familial hypercholesterolemia, novel therapies for lowering LDL-C beyond statin therapy, the status of lipoprotein(a) as a causal risk factor and newer therapeutic approaches to address it, the evaluation and management of dyslipidemia in children, current and emerging therapies for hypertriglyceridemia, and nutraceuticals to treat dyslipidemia in patients with COVID-19. This Special Issue will discuss state-of-the-art clinical trials and other research developments regarding newer and emerging therapies for the management of dyslipidemia to reduce the residual risks of ASCVD. The hope is to provide clinicians with the latest information on the key aspects of the evaluation and treatment of dyslipidemia, including newer non-statin approaches for decreasing the residual risks of ASCVD, such as the settings of elevated LDL-C, lipoprotein(a), and familial hypercholesterolemia.